Thierry Poynard
#85,947
Most Influential Person Now
Researcher
Thierry Poynard's AcademicInfluence.com Rankings
Thierry Poynardphilosophy Degrees
Philosophy
#3079
World Rank
#5059
Historical Rank
Logic
#939
World Rank
#1528
Historical Rank
Download Badge
Philosophy
Thierry Poynard's Degrees
- PhD Medicine Université Paris Cité
- Doctorate Medicine Université Paris Cité
Why Is Thierry Poynard Influential?
(Suggest an Edit or Addition)Thierry Poynard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- An algorithm for the grading of activity in chronic hepatitis C (1996) (3875)
- Natural history of liver fibrosis progression in patients with chronic hepatitis C (1997) (3161)
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (1998) (2325)
- Viral hepatitis B (2003) (1770)
- Sampling variability of liver biopsy in nonalcoholic fatty liver disease. (2005) (1766)
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study (2001) (1467)
- Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients (1999) (1286)
- Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. (2002) (1172)
- Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. (2002) (1056)
- Liver fibrosis in overweight patients. (2000) (951)
- Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
- Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis (1999) (799)
- Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. (2001) (774)
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (2010) (739)
- Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration (1996) (733)
- Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. (2009) (646)
- Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C (2003) (622)
- Estimating future hepatitis C morbidity, mortality, and costs in the United States. (2000) (607)
- Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. (2008) (569)
- Impact of hepatitis B and C virus on kidney transplantation outcome (1999) (517)
- Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis (2002) (476)
- Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (2006) (474)
- Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States (2013) (468)
- A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. (1995) (468)
- Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. (1981) (467)
- Extrahepatic manifestations of chronic hepatitis C (1999) (466)
- Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy (2001) (465)
- A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. (2005) (451)
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. (2013) (449)
- A novel dendritic cell subset involved in tumor immunosurveillance (2006) (448)
- Viral hepatitis C (2003) (448)
- A comparison of fibrosis progression in chronic liver diseases. (2003) (447)
- Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients (1999) (437)
- Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. (1991) (435)
- Multivariate analysis of prognostic factors in fulminant hepatitis B (1986) (429)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. (2002) (414)
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. (2013) (410)
- Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (2000) (405)
- Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial (1996) (387)
- Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C (2004) (379)
- Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome (2001) (364)
- A randomized trial of prednisolone in patients with severe alcoholic hepatitis. (1992) (354)
- Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. (2003) (352)
- Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial (2010) (349)
- Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. (2004) (342)
- The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis (2005) (342)
- Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity (1998) (327)
- Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. (2002) (322)
- Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. (2010) (321)
- Meta-analyses of FibroTest diagnostic value in chronic liver disease (2007) (320)
- Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C (1998) (311)
- Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study (2001) (306)
- Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C (2000) (294)
- NAFLD and liver transplantation: Current burden and expected challenges. (2016) (292)
- Corticosteroids and peptic ulcer: meta‐analysis of adverse events during steroid therapy (1994) (287)
- Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease (2006) (286)
- Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. (1999) (285)
- Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus (1997) (284)
- Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. (2014) (272)
- A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report (1984) (271)
- Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. (1999) (267)
- Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin (2003) (266)
- Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. (1996) (261)
- Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease (2009) (259)
- Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. (2009) (258)
- A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. (2006) (252)
- Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. (2007) (251)
- Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. (1999) (251)
- A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. (2005) (245)
- Beta‐adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta‐analysis (1997) (242)
- Natural history and predictors of disease severity in chronic hepatitis C. (2006) (241)
- Model for end‐stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure (2007) (240)
- Modeling the hepatitis C virus epidemic in france (1999) (235)
- In situ detection of lipid peroxidation by‐products in chronic liver diseases (1997) (233)
- Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial (2002) (231)
- Fatigue in patients with chronic hepatitis C (2002) (228)
- Transforming growth factor—beta 1 (TGF‐β1) and TGF‐β1 receptors in normal, cirrhotic, and neoplastic human livers (1995) (217)
- Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients (2003) (214)
- Factors that predict response of patients with hepatitis C virus infection to boceprevir. (2012) (209)
- In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. (1997) (204)
- Appropriateness of liver biopsy. (2000) (203)
- Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. (2009) (203)
- The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. (2000) (201)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Trends in primary liver cancer (1998) (196)
- Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. (2002) (193)
- Critical comparison of elastography methods to assess chronic liver disease (2016) (189)
- Fibrosis in patients with chronic hepatitis C: detection and significance. (2000) (187)
- Free Human Chorionic Gonadotropin β Subunit in Gonadal and Nongonadal Neoplasms (1992) (184)
- Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) (2007) (182)
- Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men (1996) (181)
- Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest) (2010) (175)
- Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. (2013) (171)
- A simple biological index for detection of alcoholic liver disease in drinkers. (1991) (167)
- Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States (2007) (167)
- Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. (2005) (166)
- Fibrogenic impact of high serum glucose in chronic hepatitis C. (2003) (162)
- Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. (1999) (155)
- Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. (2012) (155)
- Progression of liver fibrosis in women infected with hepatitis C: Long‐term benefit of estrogen exposure (2004) (154)
- The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. (1985) (154)
- IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes (2012) (153)
- Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants (2006) (152)
- Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. (2016) (148)
- Autoimmune chronic hepatitis exacerbated by alpha-interferon. (1992) (146)
- Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors (2004) (144)
- Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. (2013) (143)
- Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort (2018) (142)
- Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study (2002) (140)
- Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. (2008) (139)
- Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. (2010) (137)
- Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus‐1 mono‐infected patients on antiretroviral therapy (2009) (136)
- Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection (2005) (135)
- Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma (2008) (132)
- Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. (1988) (132)
- FibroTest-ActiTest as a non-invasive marker of liver fibrosis. (2008) (130)
- Natural history of HCV infection. (2000) (129)
- Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data (2012) (127)
- Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives: A case-control study (1986) (126)
- Intrahepatic virus‐specific IL‐10‐producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (2006) (126)
- Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. (2017) (125)
- Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). (2006) (123)
- In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir (2003) (123)
- A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease (2002) (122)
- Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study (2002) (122)
- Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study* (2002) (121)
- Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin (2002) (118)
- Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. (2000) (116)
- Non‐invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study (2006) (115)
- Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. (2004) (114)
- Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. (2010) (114)
- Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? (2006) (114)
- Truth Survival in Clinical Research: An Evidence-Based Requiem? (2002) (113)
- Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. (2004) (112)
- The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (2004) (110)
- Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. (1995) (109)
- Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. (2001) (109)
- Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. (2008) (108)
- Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients (1995) (108)
- Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. (1986) (107)
- Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. (1999) (107)
- Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). (2014) (107)
- Observer variation in assessment of liver biopsies of alcoholic patients. (1988) (106)
- Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency (2008) (106)
- Noninvasive prediction of fibrosis in patients with chronic hepatitis C (2003) (105)
- Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta‐analysis (2002) (104)
- Early‐TIPSS placement prevents rebleeding in high‐risk patients with variceal bleeding, without improving survival (2014) (103)
- Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. (1996) (103)
- Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index (2004) (102)
- Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. (2011) (102)
- Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. (2002) (100)
- Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. (2012) (99)
- Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report (2000) (98)
- Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. (2011) (98)
- Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding (1987) (98)
- Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers (2008) (97)
- Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation (2007) (97)
- Alpha-2-macroglobulin and hepatic fibrosis (1994) (97)
- Impact of common risk factors of fibrosis progression in chronic hepatitis C (2014) (96)
- Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C (2002) (95)
- Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. (2002) (95)
- The new paradigm of hepatitis C therapy: integration of oral therapies into best practices (2013) (95)
- Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum. (1980) (94)
- 8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2012) (93)
- Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. (2004) (93)
- Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. (2006) (92)
- Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (2000) (92)
- Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. (1997) (91)
- Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls (1994) (91)
- Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B (2015) (88)
- Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. (2012) (88)
- Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers (2010) (88)
- Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease (2016) (86)
- Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update (2001) (85)
- Independent risk factors for hepatocellular carcinoma in french drinkers (1991) (85)
- Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease (1998) (84)
- Relationship between the Fibrotest and portal hypertension in patients with liver disease (2007) (83)
- Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis (2012) (83)
- A randomized clinical trial of supplementary parenteral nutrition in jaundiced alcoholic cirrhotic patients (1986) (83)
- Fatty liver is an independent predictor of early carotid atherosclerosis. (2016) (81)
- IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy (2011) (81)
- Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c (2000) (80)
- Prognostic value of liver fibrosis biomarkers: a meta-analysis. (2011) (79)
- Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. (2017) (79)
- An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load (2008) (78)
- 12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY (2011) (78)
- Acetaldehyde‐modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis (1994) (78)
- Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin (2013) (77)
- Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. (2011) (77)
- Interferon for interferon naive patients with chronic hepatitis C. (2002) (77)
- Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model (2002) (75)
- Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Coinfected with HBV and Human Immunodeficiency Virus (1999) (75)
- Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (2003) (75)
- Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability (2007) (74)
- Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious (2006) (73)
- A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine (2006) (71)
- Cystic Fibrosis–related Liver Disease: Research Challenges and Future Perspectives (2017) (71)
- Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. (2010) (71)
- Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference (2016) (70)
- Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. (2012) (70)
- Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference (2016) (70)
- Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe (1999) (69)
- Risk factors for liver fibrosis progression in patients with chronic hepatitis C. (2003) (69)
- Blood oxidative stress markers are unreliable markers of hepatic steatosis (2006) (67)
- Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia (2006) (67)
- Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age (2011) (67)
- Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies (2010) (66)
- Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B (2011) (66)
- Comparing the public health burden of chronic hepatitis C and HIV infection in France. (2004) (66)
- Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. (1995) (65)
- Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. (2013) (65)
- Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. (2008) (64)
- FibroMAX™: towards a new universal biomarker of liver disease? (2007) (64)
- High‐density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats (2007) (64)
- Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. (2009) (63)
- Psoriasis, alcohol, and liver disease. (1985) (63)
- Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. (2002) (63)
- Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status (2006) (63)
- Anticardiolipin, anti-beta2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia. Multivirc Group. (1997) (62)
- Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. (2006) (62)
- Sarcoidosis and interferon therapy: report of five cases and review of the literature. (2003) (61)
- The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C (2003) (59)
- Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. (2006) (59)
- Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. (2015) (59)
- Prednisone‐interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis (1994) (59)
- Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. (2008) (58)
- Portal hypertensive colopathy (1991) (58)
- Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. (2000) (58)
- Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy (2003) (57)
- A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. (2002) (57)
- FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis? (2005) (56)
- An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. (2015) (56)
- Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series (2007) (55)
- The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. (2006) (55)
- Interferon for acute hepatitis C. (2001) (54)
- Long‐term Efficacy of Interferon‐Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis (2019) (54)
- Response to interferon α treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus (1999) (54)
- 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
- Efficiency of respiratory assistance in cirrhotic patients with liver failure (2005) (52)
- Fat, diabetes, and liver injury in chronic hepatitis C (2004) (51)
- Assessment of Liver Fibrosis: Noninvasive Means (2008) (51)
- Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome (1994) (51)
- Diagnostic value of serum protein profiling by SELDI‐TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C (2007) (50)
- Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest–ActiTest) in patients infected by hepatitis B virus (2009) (50)
- Prognostic Value of Total Serum Bilirubin/γ‐Glutamyl Transpeptidase Ratio in Cirrhotic Patients (1984) (50)
- Ethanol‐induced inhibition of cytokine release and protein degranulation in human neutrophils (2002) (49)
- Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. (2015) (49)
- Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. (1998) (49)
- Portal lymphocytic infiltrate in alcoholic liver disease. (2002) (49)
- Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. (1999) (49)
- [Treatment and prevention of hepatitis C]. (2000) (48)
- Biomarkers of liver fibrosis. (2008) (48)
- Mechanisms of alcoholic liver disease: cytokines. (2001) (48)
- Adrenocorticosteroid administration and peptic ulcer: a critical analysis. (1985) (47)
- Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. (1987) (46)
- Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. (2008) (46)
- Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. (2007) (46)
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. (2001) (45)
- Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? (2005) (44)
- [Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire]. (1999) (44)
- [Evaluation of the methodological quality of randomized therapeutic trials]. (1988) (44)
- Does elective sclerotherapy improve the efficacy of long‐term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial (1992) (43)
- Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis (1998) (43)
- Histological features predictive of liver fibrosis in chronic hepatitis C infection. (1996) (42)
- Gastric phytobezoar destruction by Nd:YAG laser therapy. (1986) (42)
- Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection (2006) (42)
- Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. (2020) (42)
- Comparison of bathophenanthroline sulfonate and ferene as chromogens in colorimetric measurement of low hepatic iron concentration. (2001) (42)
- Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. (2019) (41)
- Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study (2006) (41)
- Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? (2012) (40)
- The use of transient elastography and non‐invasive serum markers of fibrosis in pediatric liver transplant recipients (2013) (40)
- Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. (2002) (39)
- Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). (2014) (39)
- Apolipoprotein AI and alcoholic liver disease (1986) (39)
- Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients (1985) (39)
- Spleen Stiffness Measurement by Transient Elastography to Diagnose Portal Hypertension in Children (2014) (39)
- 49 PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL (2009) (39)
- Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus (2018) (38)
- Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest) (2004) (38)
- 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2013) (38)
- Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre (2010) (38)
- What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). (2011) (38)
- Review article: an unexpected virus–host interaction – the hepatitis C virus‐diabetes link (2005) (37)
- Review article: critical review of meta‐analyses of randomized clinical trials in hepatogastroenterology (1997) (37)
- 219 Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B (2003) (35)
- Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant (2006) (35)
- ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. (2010) (35)
- Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns (2002) (34)
- Relations Between Effectiveness of a Diagnostic Test, Prevalence of the Disease, and Percentages of Uninterpretable Results (1982) (34)
- Relapse rate of patients after healing of oesophagitis—a prospective study of alginate as self‐care treatment for 6 months (1993) (33)
- The burden cost of French patients suffering from irritable bowel syndrome (2004) (33)
- FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. (2011) (33)
- NASH: a hidden and silent fibroser finally revealed? (2005) (32)
- Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation (1990) (32)
- Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding. (2015) (31)
- Effects of interferon therapy in "non responder" patients with chronic hepatitis C. (1999) (31)
- Hepatitis C: Somber views of natural history and optimistic views of interferon treatment? (1998) (31)
- Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B (2004) (30)
- 988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM (2008) (30)
- Cirrhosis as an independent risk factor for colonic adenomas. (1992) (30)
- Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients. (1989) (29)
- Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. (2012) (29)
- Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences (1999) (29)
- Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. (1999) (29)
- Management of hepatitis C (1998) (29)
- Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. (1995) (29)
- Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. (1993) (29)
- PRURIT ET VIRUS DE L'HÉPATITE C (1998) (28)
- [Pruritus and the hepatitis C virus. The MULTIVIRC Unit]. (1998) (28)
- Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia (2014) (28)
- Applicability and variability of liver stiffness measurements according to probe position. (2009) (27)
- Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO (2007) (27)
- Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study (2015) (27)
- First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. (2011) (27)
- Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. (2012) (26)
- No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia (1998) (26)
- Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison (2016) (26)
- Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"? (2011) (25)
- Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. (2010) (25)
- RECTAL AND COLONIC VARICES IN CIRRHOSIS (1989) (25)
- Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. (2006) (25)
- Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury (2016) (25)
- Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. (2004) (25)
- Diagnostic value of serum gamma-glutamyl-transferase activity and mean corpuscular volume in alcoholic patients with or without cirrhosis. (1990) (25)
- Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. (2015) (25)
- Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV (2002) (24)
- Localization of apolipoprotein A-I and apolipoprotein A-II in human atherosclerotic arteries. (1989) (24)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus (2010) (24)
- Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease (2018) (23)
- Anti—pre‐S responses and viral clearance in chronic hepatitis B virus infection (1992) (23)
- Secretory diarrhea and prostaglandin D2 overproduction in systemic mastocytosis. (1982) (23)
- Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. (2008) (23)
- Binding of apolipoprotein A‐I and acetaldehyde‐modified apolipoprotein A‐I to liver extracellular matrix (1996) (23)
- Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores (2006) (22)
- Visible abdominal distension and gas surface: description of an automatic method of evaluation and application to patients with irritable bowel syndrome and dyspepsia (1992) (22)
- Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective (2018) (22)
- Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers (2012) (22)
- Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. (1995) (22)
- Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. (2009) (21)
- Diaphragm function is not impaired by pneumoperitoneum after laparoscopy. (1993) (21)
- Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin. (2017) (21)
- FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. (2011) (21)
- The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. (2004) (21)
- Perspectives on Fibrosis Progression in Hepatitis C: An à la Carte Approach to Risk Factors and Staging of Fibrosis (2010) (21)
- French experience of Manning's criteria in the irritable bowel syndrome (1992) (21)
- 42 Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B (2004) (20)
- Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure (2003) (20)
- Interferon γ receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection (2010) (20)
- Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis (1998) (20)
- Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial (2003) (20)
- Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. (1998) (20)
- Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. (2003) (19)
- A reference material for traceability of aspartate aminotransferase (AST) results (2005) (19)
- Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? (2003) (19)
- Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. (1984) (19)
- Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis. (2012) (19)
- The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. (2014) (19)
- 738 A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non-alcoholic steatohepatitis: Results of the flirt pilot trial (2006) (19)
- 706 SUSTAINED DURABILITY OF HBEAG SEROCONVERSION IN CHRONIC HEPATITIS B PATIENTS AFTER TREATMENT WITH TELBIVUDINE (2008) (19)
- Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results (2005) (18)
- Quantification of apolipoprotein A‐I and B messenger RNA in heavy drinkers according to liver disease (1996) (18)
- Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification. (2015) (18)
- Touching some firm ground in the epidemiology of NASH. (2012) (18)
- 744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up (2006) (18)
- FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase‐to‐platelet ratio index in patients with chronic hepatitis C (2007) (18)
- Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. (2007) (18)
- Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. (1999) (18)
- [Factors related to 30th day mortality in upper digestive tract hemorrhage in cirrhotic patients (author's transl)]. (1980) (17)
- Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. (2012) (17)
- Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis (1987) (17)
- Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study (2012) (17)
- Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV–hepatitis C virus co-infection (2003) (17)
- Continuous infusion of high‐dose omeprazole is more effective than standard‐dose omeprazole in patients with high‐risk peptic ulcer bleeding: a retrospective study (2007) (17)
- A prospective assessment of an ‘a la carte’ regimen of PEG‐interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers (2006) (16)
- Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer (1990) (16)
- The elusiveness of “normal” ALT in fatty liver (2004) (16)
- [Multidimensional analysis by Cox's model of the survival of patients with alcoholic cirrhosis]. (1986) (16)
- Adrenocorticosteroid therapy and peptic-ulcer disease. (1984) (16)
- Efficacy and safety of lansoprazole 15 mg oad or 30mg oad as one year maintenance treatment for erosive reflux esophagitis. A randomized trial (1995) (16)
- FAS promoter polymorphisms correlate with activity grade in hepatitis C patients (2005) (16)
- Worsening of steatosis and fibrosis progression (2003) (16)
- Treatment of hepatitis C virus: the first decade. (2004) (16)
- HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. (2011) (15)
- Lower expression of CD81 B‐cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection (2003) (15)
- [Systemic circulatory hyperkinetic syndrome in patients with cirrhosis. Relation with hepatocellular failure and portal hypertension]. (1984) (15)
- 1158 Long term treatment with adefovir dipivoxil (ADV) for three years in patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement (2003) (14)
- Predictive value of alt levels on histological findings in chronic hepatitis C: a European collaborative study (2001) (14)
- Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference (2018) (14)
- Apolipoprotein A1 and hepatic fibrosis. (1995) (14)
- 729 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (2003) (14)
- Hémostase endoscopique des hémorragies ulcéreuses gastro-duodénales : méta-analyse des essais randomisés (1991) (14)
- The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption (2009) (13)
- Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. (1996) (13)
- A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus‐coinfected patients (2016) (13)
- Laboratory Testing for Liver Disease (2012) (13)
- Successful ablation of a large fibrovascular polyp of the esophagus by endoscopic Nd:YAG laser therapy. (1989) (13)
- Serial passage of West‐European sporadic non‐A non‐B hepatitis in rhesus monkeys by inoculation with fecal extracts (1990) (13)
- Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis (2015) (13)
- Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. (2005) (13)
- Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?". (2014) (13)
- Diagnostic value of FibroTest with normal serum aminotransferases (2006) (13)
- Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin (1997) (13)
- Lamivudine and HBV-associated nephropathy. (2006) (13)
- A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. (2010) (13)
- Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. (1996) (13)
- Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis (2020) (13)
- The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. (2008) (13)
- Liver biopsy: the best standard...when everything else fails. (2009) (13)
- Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel. (1990) (12)
- Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests. (2012) (12)
- Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery (2017) (12)
- [Meta-analysis of clinical trials]. (1991) (12)
- A biphasic pattern of anti‐pre‐s responses in acute hepatitis B virus infection (1990) (12)
- Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV. (2009) (12)
- Treatment of chronic hepatitis C by interferon for longer duration than six months (1996) (12)
- A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis (2012) (12)
- Chronic hepatitis B treatment with lamivudine in kidney transplant patients. (2000) (12)
- [493] ADEFOVIR SALVAGE THERAPY FOR VIROLOGIC BREAKTHROUGH IN TELBIVUDINE-TREATED PATIENTS FROM THE GLOBE STUDY (2007) (12)
- Hirsch Index and Truth Survival in Clinical Research (2010) (12)
- Uses of error. (2002) (12)
- Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. (2001) (12)
- FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence (2008) (11)
- Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients (2002) (11)
- BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease (2016) (11)
- The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis (2018) (11)
- Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. (1996) (11)
- Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C (2001) (11)
- 162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial (2008) (11)
- Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients (2002) (11)
- [Palliative treatment of cancers of the esophagus and cardia with neodymium YAG laser: short-term results and multidimensional analysis of factors related to functional improvement and tumor destruction]. (1987) (11)
- Transférabilité des résultats entre les automates RXL, ARX, X-Pand, BN2 (Dade Behring) et le Modular DP (Roche Diagnostics) : application aux paramètres des Fibrotest et Actitest (2005) (11)
- Traitement de l'hypertension portale. Recommandations. Club Francophone pour l'Etude de l'Hypertension Portale. (1999) (11)
- Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 (2020) (11)
- The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C (2003) (11)
- LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis (2018) (11)
- Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? (2009) (10)
- Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection. (2013) (10)
- Clinical course and prognosis of 91 patients with cirrhosis and type 1 hepatorenal syndrome (HRS) treated with terlipressin: a retrospective multicenter study (2001) (10)
- Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. (2018) (10)
- Computer-aided decision support in hepatology. (1992) (10)
- NNRTI‐related or ‐unrelated hepatotoxicity? (2002) (10)
- Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression. (1997) (10)
- Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. (2002) (10)
- Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms (2015) (10)
- Impact of steatosis and inflammation definitions on the performance of NASH tests (2017) (10)
- 86 Diagnostic value of two new biomarkers (steatotest and NASHtest) for the prediction of steatosis and non-alcoholic steato-hepatitis (NASH) (2006) (9)
- [Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest]. (2005) (9)
- Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. (2013) (9)
- Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events? (2011) (9)
- [Prevalence of serum anti-hepatitis C virus antibodies and risk factors of contamination in the personnel of a hospital in the Paris region. A prospective survey]. (1996) (9)
- The role of interleukin-10 in severe acute alcoholic hepatitis. (2001) (9)
- [Palliative treatment of cancers of the esophagus and cardia with YAG neodymium laser. (Preliminary noncontrolled trial)]. (1984) (9)
- Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity (2015) (9)
- Treatment of cirrhotic patients in the pegylated interferon era. (2004) (9)
- A short induction regimen of interferon‐α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial (1999) (9)
- Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C (2003) (9)
- [CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study]. (2001) (9)
- Prolonged therapy for hepatitis C with low-dose peginterferon. (2009) (9)
- Perioperative management of combined heart–liver transplantation in patients with cirrhosis, renal insufficiency, or pulmonary hypertension (2011) (8)
- [Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis]. (1998) (8)
- [Analgesic effect of transcutaneous cranial electrostimulation in patients treated by Nd:YAG laser for cancer of the rectum. A double-blind randomized trial]. (1992) (8)
- Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. (2019) (8)
- Lymphome du MALT hépatique de bas grade de malignité associé à une cirrhose biliaire primitive (2003) (8)
- [Simultaneous detection of IgM antibodies against the hepatitis A virus and the viral capsid antigen of Epstein-Barr virus in acute hepatitis]. (1985) (8)
- [Hepatic involvement in HIV 1 virus infection]. (1988) (8)
- Sensitivity, specificity and predictive values of the secretin infusion test in the diagnosis of gastrinoma. (1986) (8)
- [Peri-anal ulceration. Tuberculosis should not be overlooked]. (1984) (8)
- Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography. (2019) (8)
- Effect of terlipressine (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patietns: Results of a pilot study (1998) (7)
- Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. (2007) (7)
- [Isolated ascites revealing a hypothyroidism. Study of 2 cases]. (1998) (7)
- Toxicité hépatique de la chimiothérapie du cancer colorectal métastatique : revue de la littérature (2010) (7)
- Dosage immunoturbidimétrique de l'alpha 2 macroglobuline (réactifs DakoCytomation) sur les automates Roche Diagnostics (Modular P, Cobas Intégra). Application au FibroTest-ActiTest® (2005) (7)
- [Acute tuberculous pancreatitis in a patient with acquired immunodeficiency syndrome]. (1990) (7)
- [Descriptive epidemiology of patients with alcoholic liver disease hospitalized in a hepato-gastroenterology service]. (1999) (7)
- Performances of Elasto-FibroTest ® , a combination between FibroTest ® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C (2012) (7)
- Age and gender will survive to competing risks as fibrosis factors. (2005) (7)
- [Palliative treatment of adenocarcinoma of the rectum by Nd-YAG laser. Immediate and long-term results. Study of factors related to the initial destruction of the tumor]. (1986) (7)
- Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. (2013) (7)
- [Non-invasive evaluation of liver fibrosis in hepatitis C]. (2008) (7)
- Ulcération péri-anale: ne pas oublier la tuberculose (1984) (7)
- [Serum lipoproteins and alcoholic diseases of the liver]. (1987) (7)
- [58] SUSTAINED OFF-TREATMENT HBeAg RESPONSE IN TELBIVUDINE AND LAMIVUDINE TREATED HBeAg-POSITIVE PATIENTS FROM THE GLOBE STUDY (2007) (7)
- Prednisolone markedly improves short-term survival of patients with severe biopsy-proven alcoholic hepatitis. A double blind randomized bicenter trial (1991) (6)
- 439 Improving antiviral therapy in chronic hepatitis B: Maximal viral suppression at week 24 correlates with better clinical efficacy at one year (2004) (6)
- [Treatment of gastroesophageal reflux: analysis of randomized double-blind trials]. (1987) (6)
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study. (2004) (6)
- Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. (2018) (6)
- 295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy: (2009) (6)
- Les interférons ont-ils une action antifibrosante ?Le point de vue de l'hépatologue (2002) (6)
- CA 16-Méta-analyses du fibrotest (FT) pour le diagnostic de fibrose dans les 4 maladies du foie les plus fréquentes (2006) (6)
- [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]. (2010) (6)
- Hepatitis C and B : management and treatment (2004) (6)
- Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospital. (2020) (6)
- A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group. (1999) (6)
- Acute hepatitis during hypersensitivity syndrome due to midecamycin. (1997) (6)
- Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing (2019) (6)
- [Is fluindione hepatotoxic?]. (1990) (6)
- [Ulcerative colitis caused by Histoplasma capsulatum in a patient with the acquired immunodeficiency syndrome]. (1986) (6)
- High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients (2010) (6)
- Adenocarcinoma of the Vater's ampulla and von Recklinghausen disease. (1987) (6)
- Early use of TIPS for cirrhosis and variceal bleeding. (2010) (6)
- Gastric mucormycosis: a rare cause of gastrointestinal bleeding in cirrhosis. (2012) (6)
- [755] UTILITY OF A COMBINATION OF NON-INVASIVE BIOMARKERS (FIBROMAX) IN ASSESSING THE EFFICACY OF ROSIGLITAZONE IN A ONE YEAR RANDOMIZED, DOUBLE-BLIND TRIAL IN NON ALCOHOLIC STEATOHEPATITIS (2007) (6)
- Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
- [Randomized double-blind trial with a liquid suspension of alginate for the treatment of pyrosis]. (1991) (6)
- Serum Apolipoprotein A‐I in Alcoholic Patients with Chronic Calcifying Pancreatitis (1990) (5)
- 552 Comparing the public health burden of chronic hepatitis C and HIV infection in United States (2003) (5)
- Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. (2008) (5)
- [Mucosa-associated lyphoid tissue hepatic lymphoma with low-grade malignancy associated with primary biliary cirrhosis]. (2003) (5)
- [Semiology of gastroduodenal ulcer proved by endoscopy: epidemiological analysis of 1,800 cases]. (1988) (5)
- Statistics in clinical trials (1990) (5)
- Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH (2009) (5)
- The European IMI SAFE-T Consortium: Qualification of translational safety biomarkers☆ (2009) (5)
- Endoscopic laser therapy for duodenal villous adenoma (1989) (5)
- Individual and evidence-based (2002) (5)
- Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C (2004) (5)
- A randomized study of a coaxial fiber versus a naked fiber for endoscopic Nd:YAG laser therapy of esophageal and rectal tumors. (1989) (5)
- Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes (2019) (5)
- [513] EFFICACY OF TELBIVUDINE VS LAMIVUDINE AT 2 YEARS IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B WHO ARE ELIGIBLE FOR TREATMENT BASED ON GUIDELINES (2007) (5)
- Hepatitis B and C (2001) (5)
- P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta (2015) (5)
- Summary of the first international symposium on viral hepatitis. (1999) (5)
- Stéatopathies non alcooliques : limites de nos connaissances et leçons pour l'hépatologue d'aujourd'hui (2003) (5)
- Évaluation non-invasive de la fibrose hépatique au cours de l'hépatite C (2008) (5)
- Hepatitis E infection in patients with severe alcoholic hepatitis: is there a place for systematic screening? (2015) (5)
- CO 12-La prévalence de chaque stade de fibrose est un facteur majeur de variabilité de l’estimation de la valeur diagnostique des marqueurs de fibrose par les courbes ROC (2006) (5)
- [Endoscopic hemostasis for hemorrhagic gastroduodenal ulcer. Meta-analysis of randomized clinical trials]. (1991) (5)
- [Relationship between mean corpuscular volume, alcohol consumption, smoking habits, and alcoholic liver disease in hospitalized patients (author's transl)]. (1979) (5)
- LA FLUINDIONE EST-ELLE HEPATOTOXIQUE ? (1990) (5)
- 559 An overview of biochemical markers (fibrotest-actitest) diagnostic value in chronic liver diseases: A non-invasive alternative to liver biopsy (2003) (5)
- Hepatocellular Carcinoma in NAFLD (2007) (5)
- 597 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (2004) (5)
- Infections with Multiple Hepatotropic Viruses (2002) (5)
- Efficacy of long term recombinant interferon-alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study. (1991) (5)
- Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy (2003) (5)
- Heptitis B and C virus infection in HBsAg-negative alcoholics without i.v. drug abuse or previous blood transfusions (1995) (4)
- [240] APPLICABILITY OF NON-INVASIVE METHODS FOR THE DIAGNOSIS OF LIVER INJURY, LIVER STIFFNESS MEASURES (LSM) OR BIOMARKERS, AND FACTORS ASSOCIATED WITH NON-APPLICABILITY (2007) (4)
- Impact of high serum glucose on liver fibrosis in chronic hepatitis C (CHC) (2001) (4)
- [Do the interferons have an antifibrotic action? The hepatologist's point of view]. (2002) (4)
- Rate of employment after liver transplantation in France: a single-centre study (2015) (4)
- Improvement of histological lesions by 18 months therapy with $alpha;2B interferon (IFN 2B) in patients with chronic hepatitis C. A randomized clinical trial (1993) (4)
- [Lipid peroxidation, free radicals and alcoholic liver diseases]. (1986) (4)
- Mutants pré-C du VHB (2002) (4)
- [Nonalcoholic fatty liver disease: 30 years research changed NASH]. (2009) (4)
- Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. (2002) (4)
- [Influence of anemia on hemodynamic changes in patients with cirrhosis]. (1997) (4)
- Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI) (2013) (4)
- Truth survival. Authors' reply (2002) (4)
- [Evaluation of hepatitis B vaccination in a Paris hospital personnel. 386 subjects]. (1987) (4)
- Neuronopathie sensitive associée à une hépatite chronique auto-immune. (1997) (4)
- Asian Pacific Association for Study of the Liver (APASL) (2003) (4)
- Périhépatite à Chlamydia trachomatis. Etude de cinq cas et revue de la littérature. (1982) (4)
- Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C (2007) (4)
- Progression of Fibrosis (2007) (4)
- Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus‐infected patients treated with pegylated interferon plus ribavirin and rituximab (2012) (4)
- Methodological problems of randomized clinical trials in the treatment of duodenal ulcer, "gastritis" and Campylobacter pylori infection. (1989) (4)
- Perisinusoidal cells (Ito-cells) enlargement in a family with myotonic dystrophy. (2008) (4)
- [A new fatal case of hepatitis caused by clometacin]. (1983) (4)
- Spontaneous ascitic fluid infection and bacteremia due to Yersinia pseudotuberculosis in a liver transplant patient. (2015) (4)
- 1075 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD) (2003) (4)
- Recherche d'une infection à cytomégalovirus au cours des colites pseudo-membraneuses. 6 observations. (1981) (4)
- A DECADE OF CAMPYLOBACTER PYLORI (1988) (4)
- [Nodular regenerative hyperplasia and pulmonary arterial hypertension]. (1990) (4)
- Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%. (2013) (4)
- Are alcoholic beverages equivalent in their potential to cause alcoholic liver disease (1991) (4)
- Safety and efficacy of adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients (2001) (3)
- No effect of neutralizing antibody to TGF-beta 1 in acute CC14-induced liver fibrogenesis. (1994) (3)
- [Non invasive markers using for the assessment of fibrosis in hepatitis C]. (2007) (3)
- Randomized double-blind clinical trial of aluminum phosphate versus ranitidine in the acute treatment of duodenal ulcer. (1990) (3)
- BRIP 1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV-or HBV-related liver disease (2019) (3)
- Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection (2013) (3)
- Indications et résultats de la transplantation hépatique dans la cirrhose alcoolique (1999) (3)
- Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease (2013) (3)
- PREDNISOLONE IN SEVERE ALCOHOLIC HEPATITIS. AUTHOR'S REPLY (1992) (3)
- Faut-il encore faire des biopsies du foie ? (2007) (3)
- Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests (2015) (3)
- Histoire naturelle de l'hépatite C (2002) (3)
- Pharmacological treatment for alcoholic hepatitis and cirrhosis: present practice and future strategies (2002) (3)
- [Should we have the courage to say no to systematic liver biopsy?]. (2003) (3)
- 21 10-YEARS PROGNOSTIC VALUE OF FIBROTEST AND STEATOTEST FOR LIVER-RELATED AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE-2 DIABETES AND/OR HYPERLIPIDEMIA (2013) (3)
- The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test (2011) (3)
- FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted. (2011) (3)
- A cooperative study on the detection of colorectal cancer and polyps in France. (1981) (3)
- External validation of an algorithm combining multi‐analyte blood tests (FibroTest‐LCR1‐LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease (2019) (3)
- [Randomized therapeutic trials in the treatment of acute pancreatitis]. (1986) (3)
- [Critical study of gastroduodenal complications of corticotherapy]. (1990) (3)
- Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. (2020) (3)
- Efficacy and safety of interferon and ribavirin therapy in HIV-HCV coinfected patients (2000) (3)
- Hémorragie digestive basse récidivante de l'adulte jeune: une indication opératoire. (1997) (3)
- [Corticosteroid therapy in acute severe alcoholic hepatitis: the end of a controversy?]. (1998) (3)
- External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV (2021) (3)
- 1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY (2010) (3)
- [Recurrent lower digestive hemorrhage in young adults: a surgical indication]. (1997) (3)
- [Chlamydia trachomatis perihepatitis (author's transl)]. (1982) (3)
- Epidémiologie et méthodologie des essais thérapeutiques randomisés chez les sujets atteints de troubles fonctionnels intestinaux (1990) (3)
- P832 CLINICAL VALIDATION OF THE FLIP ALGORITHM AND SAF SCORE IN NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (3)
- Diagnosis and treatment of viral liver fibrosis. (2005) (3)
- 1401 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES VARIANTS ASSOCIATED WITH LIVER FIBROSIS PROGRESSION IN HCV-INFECTED PATIENTS (2012) (3)
- Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon-α2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients (2008) (3)
- [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse]. (2008) (3)
- [Treatment of portal hypertension]. (1999) (2)
- [Intestinal functional disorders: review of the literature]. (1977) (2)
- β-blockers and variceal haemorrhage (1990) (2)
- Hepatitis C and B (2013) (2)
- 831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3 (2009) (2)
- Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus (2020) (2)
- Presence of metabolic syndrome and low CD4 count are independently associated with liver fibrosis in human immunodeficiency virus-infected patients with non-alcoholic fatty liver (2017) (2)
- [Hepatitis C: natural history, biology, treatment monitoring]. (1999) (2)
- Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load (2008) (2)
- Quelles sont les indications du traitement dans l'hépatite C aiguë ? (2002) (2)
- [555] FACTORS IMPROVING MANAGEMENT OF HEPATITIS C IN DRUG USERS. AN EXPERIENCE IN A DRUG ADDICT'S CENTRE (2007) (2)
- 56 LONG-TERM EFFICACY OF ROSIGLITAZONE IN NONALCOHOLIC STEATOHEPATITIS (NASH): RESULTS OF THE EXTENSION PHASE OF THE FLIRT-2 TRIAL (2009) (2)
- [Xenotransplantation in man. 2: Control of rejection and application to xenotransplantation of the swine liver in man]. (1996) (2)
- 1043 PENTOXIFYLLINE (PTX) REDUCES THE RISK OF COMPLICATIONS IN PATIENTS WITH ADVANCED CIRRHOSIS. ANALYSIS OF THE RESULTS OF A PIVOTAL PHASE 3 TRIAL (2009) (2)
- 56 Natural history of fibrosis in chronic hepatitis C (2003) (2)
- 403 CLINICALLY SIGNIFICANT VARIABILITY OF LIVER STIFFNESS MEASUREMENTS ALTERS SHORT-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC LIVER DISEASES (2010) (2)
- Adhésion à la bithérapie pégylée au cours de l’hépatite chronique C : Importance du trio hépatologue, médecin généraliste, infirmière (2008) (2)
- 224 INTEREST OF FIBROTEST-ACTITEST (FT-AT) IN THE FOLLOW-UP OF LIVER TRANSPLANTED (LT) PATIENTS: A PILOT STUDY (2008) (2)
- 822 PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE RE-TREATMENT OF PREVIOUS INTERFERON/RIBAVIRIN NON-RESPONDERS (NR): RESULTS FROM THE EPIC3 PROGRAM (2008) (2)
- Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study (2017) (2)
- Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. (2021) (2)
- S1000 Results from the Epic3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the RE-Treatment of Previous Interferon/Ribavirin Non-Responders (Nr) (2008) (2)
- [Analysis of factors related to length of stay in the hospital in a hepato-gastroenterology unit]. (1983) (2)
- Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes (2021) (2)
- Biopsy as well as FibroTest/Fibrosure Is Suboptimal for Discriminating Intermediate Fibrosis Stages in Patients With Chronic Hepatitis B (2014) (2)
- Stéatohépatite non alcoolique : 2. Aspects physiopathologiques (2002) (2)
- Hépatotoxicité du chlorhydrate de moxisylyte: un nouveau cas. (1991) (2)
- Les essais thérapeutiques randomisés dans les troubles fonctionnels intestinaux (1990) (2)
- Appropriate evidence‐based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C (2009) (2)
- Facteurs de gravité à court terme des hémorragies digestives par hypertension portale chez les sujets atteints de cirrhose. (1990) (2)
- [Proposition of a code of ethics in clinical research]. (1998) (2)
- 987 A COMPARISON BETWEEN THE HEPATORENAL ULTRASOUND INDEX AND STEATOTEST FOR THE NON-INVASIVE QUANTIFICATION OF LIVER STEATOSIS (2008) (2)
- Upper digestive tract hemorrhage in cirrhotic patients (1981) (2)
- [Sensory neuronopathy associated with chronic autoimmune hepatitis]. (1997) (2)
- Diagnostic value of fibrosis biochemical markers for the prediction of portal hypertension in chronic liver disease (2003) (2)
- Characterization of the CD4 TH1 and CD8 responses against hepatitis C virus and HIV in peripheral blood of HCV-HIV coinfected patients (2001) (1)
- Boceprevir Use in France: A Markov Model of Disease Progression and Cost-Effectiveness for Chronic Hepatitis C (Virus G1) (2013) (1)
- Subcutaneous interleukin-10 plus corticosteroids in the treatment of severe alcoholic hepatitis. Results of a pilot study (2003) (1)
- 664 AN ACCURATE DEFINITION OF THE STATUS OF INACTIVE HBSAG CARRIER (IC) BY A COMBINATION OF BIOMARKERS AND VIRAL LOAD (VL) (2008) (1)
- THE INTERNATIONAL LIVER CONGRESS 2018 European Association for the Study of the Liver (EASL) (2018) (1)
- Corrigendum to “Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C” [J Hepatol 36 (2002) 812–818] (2002) (1)
- [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test]. (2005) (1)
- Chapter 14 – Laboratory Testing for Liver Disease (2006) (1)
- 282 Diagnostic value of fibrosis biochemical markers (fibrotest) for the prediction of portal hypertension in chronic liver disease (2003) (1)
- [Hepatotoxicity of moxisylyte chlorhydrate: a new case]. (1991) (1)
- Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer (2018) (1)
- [Randomized therapeutic trials in intestinal functional disorders]. (1990) (1)
- [What are the indications for treatment of acute hepatitis C?]. (2002) (1)
- [509] WHICH PATIENTS WITH CHRONIC HEPATITIS B ARE TREATED AND HOW: A CROSS-SECTIONAL STUDY IN FRANCE ON 1790 PATIENTS (2007) (1)
- Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation. (2010) (1)
- Efficacy and safety of adefovir dipivoxil plus pegylated interferon-α 2 a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients (1)
- [Search of a cytomegalovirus infection during pseudo-membranous colitis. 6 cases (author's transl)]. (1981) (1)
- Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy. (1993) (1)
- Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19 (2022) (1)
- 5-FU/ folinic acid plus CPT-11 (FOLFIRI.3 regimen) in advanced pancreatic carcinoma (PC): results of an AGEO phase II study (2005) (1)
- 2014 IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM (2010) (1)
- 551 Projecting the prognosis of hepatic fibrosis in HIV-HCV co-infection (2003) (1)
- 224 NON-INVASIVE PREDICTION OF UPPER GASTROINTESTINAL BLEEDING BY RUPTURE OF ESOPHAGEAL VARICES (ROV) USING LIVER AND SPLEEN STIFFNESS (AIXPLORER), LIVER STIFFNESS BY FIBROSCAN AND FIBROTEST (2013) (1)
- [Development of an expert system as a teaching aid in the serological diagnosis of acute viral hepatitis]. (1987) (1)
- [Xenotransplantation in man. 1: Immunology of xenogenic graft rejection]. (1996) (1)
- [Evaluation of diagnostic methods. Application to the diagnosis of benign or malignant colonic tumours (author's transl)]. (1978) (1)
- 1021 SCREENING FOR LIVER ADVANCED FIBROSIS USING NON-INVASIVE BIOMARKER FIBROTEST IN GENERAL POPULATION (2009) (1)
- Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection (2022) (1)
- Screening studies of transient elastography and FibroTest in the general population. (2017) (1)
- [Epidemiology and methodology of randomized therapeutic trials in patients with intestinal functional disorders]. (1990) (1)
- External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B (2022) (1)
- HEPATITIS B VACCINE: A DIAGNOSTIC TEST FOR PREVIOUS HEPATITIS B VIRUS INFECTION? (1984) (1)
- [Do digestive complications of corticotherapy exist?]. (1988) (1)
- Efficacy of transplantation in patients with alcoholic cirrhosis. Evaluation using a case-control study and simulated controls (1993) (1)
- Impact of hepatitis C-associated autoantibodies (AAbs) on the liver pathology and the response to antiviral therapy (2003) (1)
- Push enteroscopy: New endoscopic method for the exploration of small bowel (1995) (1)
- O26 NAFLD IS AN INDEPENDENT PREDICTOR OF EARLY CAROTID ATHEROSCLEROSIS: RESULTS FROM A LARGE TRANSVERSAL STUDY AND LONG-TERM FOLLOW-UP VALIDATION COHORT (2014) (1)
- SAT0023 Direct-acting antiviral-based therapy restores immune tolerance in hepatitis c-induced cryoglobulinemia vasculitis (2017) (1)
- Propranolol for prevention of recurrent GI bleeding (1985) (1)
- 1164 susceptibility of wild-type and lamivudine-resistant hepatitis B virus to tenofovir and adefovir (2003) (1)
- Reduction of the observed prevalence of so-called non-A non-B hepatitis using sensitive markers of HBV and herpes viruses infections. (1987) (1)
- Interferon alfa for chronic hepatitis C infection (1999) (1)
- 468 Long term course of mixed cryoglobulinemia in hepatitis C virus-infected patients (2004) (1)
- [Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?]. (2003) (1)
- [Intestinal function disorders. Review of the literature from 1977 to 1983]. (1984) (1)
- Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD) (2018) (1)
- Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors (2004) (1)
- Prévalence des anticorps sériques anti-virus de l'hépatite C et des facteurs de risque de contamination chez le personnel d'un hôpital de la région parisienne : Une enquête prospective (1996) (1)
- Analyse descriptive des malades ayant une maladie alcoolique du foie hospitalisés dans un service d'Hépato-Gastroentérologie (1999) (1)
- Stéatohépatite non alcoolique : 1. Aspects cliniques (2002) (1)
- Traitement de l'hypertension portale (2008) (1)
- Influence d'une gaufrette contenant de la pectine sur l'hyperglycémie provoquée par un repas test chez l'homme normal (1984) (1)
- Carcinome hépatocellulaire et stéato-hépatite non alcoolique : est-ce le sommet de l'iceberg ? (2003) (1)
- Place et limites de l'automédication dans la stratégie thérapeutique du reflux gastro-œsophagien de l'adulte (1999) (1)
- Hépatite C: Histoire naturelle, biologie, surveillance du traitement (1999) (1)
- Faut-il traiter l'hépatite C? Quelles sont les indications du traitement dans l'hépatite aiguë C? (1997) (1)
- Peut-on traiter la stéatohépatite métabolique ? (2007) (1)
- 765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION (2013) (0)
- OP0235 Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: a long-term follow-up study (2018) (0)
- 546 SEVERE ALCOHOLIC HEPATITIS (AH) HAS THE SAME PROGNOSIS IN PATIENTS WITH OR WITHOUT GASTROINTESTINAL BLEEDING (GIB) (2013) (0)
- 487 LONG TERM SURVIVAL OF LIVER FIBROSIS AFTER VIROLOGICAL CURE (SVR) IN HIV–HCV COINFECTED PATIENTS: A WORRISOME LATENT DISEASE? (2013) (0)
- Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients (1988) (0)
- Long-term outcome improvement in patients with chronic hepatitis D treated with interferon α (2004) (0)
- P1002 : The histological severity of NAFLD determines the cardiovascular risk and insulin resistance in metabolically healthy and unhealthy overweight individuals (2015) (0)
- Serum lipoprotein AI:AII (LpAI:AII) Concentration is associated with liver fibrosis in drinkers but not serum lipoprotein AI (LpAI) concentration (1990) (0)
- Appropriateness of inclusion criteria according to transaminases ALT in studies assessing performances of non-invasive tests in type-2 diabetes patients (T2D) (2018) (0)
- Diagnostic value of serum apolipoprotein A-1 (APO A-1), lahinin (LA) and PIIIP for the diagnosis of fibrosis in drinkers (1989) (0)
- Final report: Part 6 – Costs and Cost effectiveness of Interventions (2002) (0)
- [Hepatic involvement in sexually transmissible diseases]. (1984) (0)
- 1356 NAFLD IS SIGNIFICANTLY INCREASED IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS AND IS CORRELATED WITH EARLY PREDICTORS OF ATHEROSCLEROSIS AND THE FRAMINGHAM SCORE (2013) (0)
- Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B (2003) (0)
- 118 METABOLIC FATTY-LIVER DISEASE INCREASES THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH ALCOHOLIC CIRRHOSIS LISTED FOR LIVER TRANSPLANTATION (2013) (0)
- Prevalence and Incidence of Subclinical Proximal Tubulopathy (SPT) over 96 Weeks in Chronic Hepatitis B (CHB) Patients Treated with Entecavir (ETV) or Tenofovir Disoproxil (TDF) without Renal Insufficiency (RI) or Hypophosphatemia during the Follow-up (2018) (0)
- [Should hepatitis C be treated? What are indications of treatment in acute hepatitis C?]. (1997) (0)
- [Modesty, uncertainty and pragmatism]. (1990) (0)
- Presence of serum HBe antibody is associated with hepatocellular carcinoma (HCC) in drinkers (1989) (0)
- Alternatives to Liver Biopsy for Assessing Liver Disease (2006) (0)
- Comparison of serum apolipoprotein-a1 (a1) and haptoglobin (hp) kinetics during sars-cov2 infection (si) in macaques and humans (2021) (0)
- Similarities and Differences Between REPEAT and EPIC3 (2009) (0)
- LP41 : Liver fibrosis epidemiology revisited using software combined biomarker: Proof of concept using 1,081,658 centralized fibrotest (FT) prescriptions (2015) (0)
- 635 Efficacy and Safety of the Combination of Entecavir (ETV)-Tenofovir (TDF) in the Treatment of Chronic Hepatitis B (CHB): A Nationwide, Retrospective Study (2010) (0)
- Possible Conflict of Interest statement. (2022) (0)
- Corticosteroids efficacy in severe alcoholic hepatitis (AH): Retrospective analysis of individual data from the American ANF French randomized contolled trials (2000) (0)
- Discordance between results of biomarkers of fibrosis shows that it is at least a "ménage à deux". (2009) (0)
- Baveno VI criteria as a prognosis index for clinical complications in patients with cirrhosis (2020) (0)
- TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION IN PATIENTS CO-INFECTED WITH HIV (2003) (0)
- Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis (2011) (0)
- Truth is not determined by a majority vote. (2003) (0)
- The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients (2015) (0)
- 1333 HCV-GENOFIBROTEST: A COMBINATION OF VIRAL, LIVER AND GENOMIC (IL28B, ITPA, UGT1A1) BIOMARKERS FOR PREDICTING TREATMENT RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C (2011) (0)
- Manifestations extrahépatiques associées au virus de l'hépatite C : étude prospective d'une cohorte de 1 614 patients (1998) (0)
- Le traitement précoce de l’infection virale C après un accident d’exposition au sang (2000) (0)
- 1355 HISTOLOGICAL SEVERITY INDEPENDENTLY PREDICTS EARLY ATHEROSCLEROTIC LESIONS AND 10 YEAR CARDIOVASCULAR RISK IN NAFLD PATIENTS (2013) (0)
- Hépatite C : le traitement (1999) (0)
- Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis (2022) (0)
- PCN26 COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER I0YEARS SCREENING USING COMPUTEDTOMOGRAPHIC COLONOGRAPHYVERSUS COLONOSCOPY AND FECAL OCCULT BLOOD TESTS (2008) (0)
- Reflux gastro-œsophagien : résultats d'un essai thérapeutique de la ranitidine chez 7846 patients (1991) (0)
- 1117-P: High Rate of Histologically Proven NASH and Advanced Fibrosis in Outpatients with Type 2 Diabetes Screened for NAFLD (2022) (0)
- HEPATOMEGALIE ET CHOLESTASE REVELATRICES D'UNE MYCOBACTERIOSE DISSEMINEE AU COURS DU SYNDROME D'IMMUNODEFICIENCE ACQUISE (1991) (0)
- Effects of Glucocorticoid Immunosuppression on Se- Rum Cystatin C Concentrations in Renal Transplant (0)
- Surrogate markers for liver fibrosis. (2005) (0)
- P1024 PRESENCE OF HEPATIC STEATOSIS AS PER NON-INVASIVE BIOMARKERS OVERESTIMATES FIBROSIS STAGES BASED ON LIVER STIFFNESS MEASUREMENT (LSM) BY TRANSIENT ELASTOGRAPHY IN TYPE-2 DIABETIC (T2D) PATIENTS (2014) (0)
- 414 IMPACT OF SHEAR-WAVES CHARACTERISTICS ON THE MEDIAN LIVER STIFFNESS MEASURE (LSM) ASSESSED BY FIBROSCAN: EVALUATION WITH LIVER BIOPSY (LB) OF RISK OF FALSE NEGATIVE RESULTS (2010) (0)
- Chapter 35 – Impact of interferon alpha-2b and of combination with ribavirin on progression of liver fibrosis in patients with chronic hepatitis C (2003) (0)
- [Cytomegalovirus hepatitis is never chronic and may hide another!]. (2001) (0)
- 346 THE HAZARDS OF TRANSAMINASE ALT VALUE AS A MARKER OF LIVER FIBROSIS PROGRESSION: A GLOBAL ASSESSMENT IN PATIENTS USING VALIDATED BIOMARKER FIBROTEST® (2011) (0)
- CD8+CD25+Foxp3+ T cells with suppressive function accumulate at tumor site in cancer colorectal patients (2008) (0)
- [Short-term severity factors of digestive hemorrhage caused by portal hypertension in patients with cirrhosis]. (1990) (0)
- Marqueurs non invasifs de fibrose hépatique. L'exemple du fibrotest (2004) (0)
- Book Review Viral Hepatitis: Diagnosis, treatment, prevention (Gastroenterology and Hepatology.) Edited by Richard A. Willson. 532 pp. New York, Marcel Dekker, 1997. $175. 0-8247-9416-8 (1997) (0)
- Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alpha. (2004) (0)
- 418 GOLD-VALIDATION OF LIVER FIBROSIS ESTIMATES, FIBROTEST (FT) AND LIVER STIFFNESS MEASUREMENT (LSM), USING SURGICAL SAMPLES AND VIRTUAL BIOPSIES (2010) (0)
- The goal of therapy is to prevent complications and death from chronic viral hepatitis [2,4]. Because of the slow evolution of chronic hepatitis over sev- (2010) (0)
- Chapter 25. Alcoholic Liver Disease (2007) (0)
- P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122 (2014) (0)
- The natural history of chronic hepatitis C: a model bridging controversies. (1999) (0)
- 440 Low HBV replication and liver fibrosis: The impact of race in a study of 552 chronic hepatitis B patients (2004) (0)
- Prognostic value of 2D-shear wave elastography for staging cirrhosis in chronic liver diseases in two severity classes according to liver-related complications (2018) (0)
- Apolipoproteinemia A and α‐fetoprotein in the diagnosis of hepatocellular carcinoma and cirrhosis: Several interpretations (1990) (0)
- 963 A COMPARISON OF THE FIBROGENIC POTENTIAL OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (HCV) BY MICROMORPHOMETRY (2008) (0)
- O.116 Reasons for the lack of anti-HBC antibody detection in hepatitis B virus chronically infected patients (2006) (0)
- [Alcoholic liver diseases excluding cirrhosis. Diagnosis, course and prognosis, principles of the treatment]. (1990) (0)
- 544 THE DISCOVERY OF BETTER BIOMARKERS OF DRUG INDUCED LIVER INJURY (DILI) NEEDS TO USE OTHER ENDPOINTS THAN ALT. A PILOT PROOF OF CONCEPT STUDY (2013) (0)
- Reply: (2005) (0)
- Resultats preliminaires d’une etude comparative du coloscanner (coloscopie virtuelle) et de l’endoscopique colique dans la detection des polypes colorectaux (2005) (0)
- Influence de la coinfection par le VIH sur l'âge et la cause du décès chez les patients atteints de cirrhose virale C (2008) (0)
- Liver Fibrosis Evaluation Using Real-Time Shear Wave Elastography: Applicability, Association with Activity and Steatosis, and Diagnostic Performance. Direct Comparisons with Transient Rlastography Using Biomarkers as References (2016) (0)
- PS-191-External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease (2019) (0)
- beta-blockers and variceal haemorrhage. (1990) (0)
- 345 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY (2010) (0)
- 949 Low HBV replication and liver fibrosis: the impact of race in a study of 552 chronic hepatitis B patients (2003) (0)
- 1064 FIBROTEST HAS NO GRAY ZONE FOR THE DIAGNOSIS OF FIBROSIS STAGES RELATIVE TO BIOPSY: THE GRAY ANATOMY OF 27869 VIRTUAL BIOPSIES AND 6500 PATIENTS (2012) (0)
- Le SIDA et le foie: atteintes hépatiques au cours de l'infection par le HIV 1 (1989) (0)
- THU-484-Mass spectrometric analysis of serum haptoglobin fucolysation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma (2019) (0)
- Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD) (2017) (0)
- Selenium status in alcoholic liver disease and HBV vaccination (1994) (0)
- Prevalence of anti-HCV antibodies in the personnel of the Antoine-Beclere Hospital (1996) (0)
- [The Fibrotest is an ethical choice because it is a cost-effective and anti-inflationistic test. Response to Jean Louis Payen and Jean Marie Combis]. (2004) (0)
- Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease (2016) (0)
- Prognostic evaluation in cirrhosis (1988) (0)
- P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study (2015) (0)
- Controlled therapeutic trials in gastroenterology. Edited by G. Dobrilla and A. Steel, 120 pp. New York: Raven Press, 1987. $56.00 (1988) (0)
- [Emergency fiberscopy in digestive hemorrhages in cirrhosis patients. Critical reflections]. (1980) (0)
- Fibrotest-Actitest : une alternative non-agressive à la biopsie du foie (2003) (0)
- [What to expect from expert systems for the diagnosis of functional bowel disorders]. (1990) (0)
- Similarities and Differences Between REPEAT and EPIC3. Authors' reply (2009) (0)
- Conflict of Interest (2019) (0)
- [Virus, Crohn's disease, ulcerative colitis and non-specific enterocolitis]. (1981) (0)
- [Disseminated Mycobacterium avium intracellulare infection revealed by hepatomegaly and cholestasis in acquired immunodeficiency syndrome]. (1991) (0)
- 1155 INTERPRETABILITY AND REFERENCE VALUES OF LIVER INJURY BIOMARKERS FIBROTEST AND ACTITEST (FT-AT). A GLOBAL ANALYSIS OF 354,143 CONSECUTIVE ASSESSMENTS (2010) (0)
- [Meta-analysis: a tool for clinical Hepato-Gastroenterology]. (1991) (0)
- [Liver and sexual freedom (author's transl)]. (1982) (0)
- Endoscopic Nd-YAG laser therapy for palliative treatment of colorectal adenocarcinoma: A multivariate prognostic analysis (1989) (0)
- [Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]. (2003) (0)
- 429 Multicenter study of hepatitis B virus (HBV) genotypes in France: Geographic distribution, correlation with HBEAG-positive status and relation to liver fibrosis (2004) (0)
- Management of treatment non responders in chronic hepatitis C. (2005) (0)
- Factors associated with first bleeding and death among cirrhotic patients treated by betablockers. Analysis of 589 cases included in four trials (1990) (0)
- P0510 : Direct comparisons of fibrotest, APRI, FIB-4, and transient elastography (TE) for the diagnosis of cirrhosis and fibrosis, in patients with chronic hepatitis C (CHC) and B (CHB) using intention to diagnose and bayesian methods. A systematic review (2015) (0)
- Blood neutrophil fbnctions and cytokine release in hepatitis effect of corticosteroids severe alcoholic (2000) (0)
- Insitu detection oflipid peroxidation inchronic hepatitis C:correlation withpathological features (1997) (0)
- P862 LONGITUDINAL VALIDATION OF BIOMARKERS OF FIBROMAX PANEL, AS SURROGATES FOR DYNAMIC HISTOLOGICAL CHANGES ON LIVER BIOPSY (LB) IN NAFLD PATIENTS (2014) (0)
- Le Fibrotest est thique car il est cot-efficace et anti-inflationniste (2004) (0)
- 582 A prospective follow-up of discordances between biochemical markers and biopsy in patients with chronic hepatis C (CHC) (2003) (0)
- A new 3 p 25 locus is associated with liver fibrosis progression in HIV / HCV co-infected patients (2016) (0)
- [Value of multidimensional analysis by Cox's model]. (1986) (0)
- [Sclerotherapy of esophageal varices using ethanol in combination with propranolol: clinical study of 30 patients]. (1988) (0)
- Editorial: simplifying screening for primary liver cancer – do the LCR1 and LCR2 tests hold the key? Authors' reply (2019) (0)
- FibroTest™ Is an Independent Predictor of Early and Sustained Virologic Response in Nonresponder Patients With Chronic Hepatitis C: Results From the EPIC 3 Study (2009) (0)
- 453 Incidence and predictive factors of mutations in the YMDD motif of the HBV polymerase after two years of lamivudine treatment for chronic hepatitis B: Results of the prospective cohort lamivir (2004) (0)
- P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic (2015) (0)
- P1039 APPLICABILITY (APP) CRITERIA FOR REAL-TIME SHEAR WAVE ELASTOGRAPHY (RT-SWE) BY AIXPLORER COMPARED TO TRANSIENT ELASTOGRAPHY (TE) BY FIBROSCAN AND TO FIBROTEST (2014) (0)
- [Role and limits of self-medication in the therapeutic strategy of gastroesophageal reflux in adults]. (1999) (0)
- L'hépatite C chez 2410 sujets âgés de 65 ans et plus : une affection sévère, curable et négligée ? (2008) (0)
- Le courage et la logique de dire non à la biopsie du foie systématique (2008) (0)
- P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France (2015) (0)
- Effet du traitement par l'interféron pégylé alpha-2B et la ribavirine sur la stéatose hépatique, chez les malades infectés par le génotype 3 du virus de l'hépatite C (2008) (0)
- 707 screening for advanced fibrosis using non-invasive biomarkers (Fibrotest Fibrosure) in diabetic patients (2006) (0)
- Hépatites : épidémiologie (2003) (0)
- Foie et liberté sexuelle. (1982) (0)
- P.371 Dépistage de la fibrose hépatique par le FibroTest en population générale (2009) (0)
- 345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY (2011) (0)
- Administration d'oméprazole par voie intraveineuse à fortes doses à la seringue électrique (IVSE) dans l'ulcère gastroduodénal hémorragique: mythe ou réalité? (2005) (0)
- Suivi de cohorte 5 ans après un traitement par fortes doses d'interféron pour hépatite chronique C (2008) (0)
- Quantification des lymphocytes T Cd8+ HCV-spécifiques circulants et intra-hépatiques à l'aide d'une combinaison de techniques de cytométrie de flux, de tri cellulaire guidés par des multimères de MHC-peptides et d'analyse immunoscope (2008) (0)
- Résultats préliminaires du coloscanner (coloscopie virtuelle) dans la détection des polypes colorectaux comparé à la coloscopie (2005) (0)
- CA18 - Analyse prospective de la valeur pronostique du fibrotest dans l’hépatite chronique C (2005) (0)
- Résistance du virus de l'hépatite B à la lamivudine chez les transplantés rénaux (2008) (0)
- CA7 - VALEUR DIAGNOSTIQUE DES MARQUEURS BIOCHIMIQUES, FIBROTEST-ACTITEST ® (FT-AT) COMPARÉS AU PROFIL PROTÉIQUE PAR SELDI-TOF PROTEINCHIP (STP), POUR LE DIAGNOSTIC DE FIBROSE CHEZ LES MALADES AYANT UNE HÉPATITE CHRONIQUE C (HCC) (2004) (0)
- Stéatose et stéatohépatite non alcooliques (2006) (0)
- Biopsie du foie contre prise de sang pour le suivi de l’hépatite C ? (2002) (0)
- Statut cagA et virulence des souches de Helicobacter pylori (2008) (0)
- Prise en charge thérapeutique de l'hépatite C chronique : quelles stratégies pour aujourd'hui et demain ? (2001) (0)
- [The liver under top protection?]. (1989) (0)
- CO29 - Précautions d’utilisation des marqueurs non-invasifs d’atteinte hépatique fibrotest-actitest® (FT-AT) chez 32 527 malades ayant une hépatite chronique C (HCC) (2004) (0)
- Impact du syndrome de l’intestin irritable (SII) sur la qualité de vie des malades (2006) (0)
- Évolution des marqueurs d’insuffisance hépatique après traitement par rituximab au cours des vascularites cryoglobulinémiques liées au virus de l’hépatite C (2010) (0)
- CO 8 - ÉTUDE DE PHASE III COMPARANT LA TELBIVUDINE A LA LAMIVUDINE CHEZ DES MALADES AYANT UNE HÉPATITE B CHRONIQUE AGHBE POSITIFS : EFFICACITÉ, TOLÉRANCE ET FACTEURS PRÉDICTIFS DE RÉPONSE A 1 AN (2006) (0)
- CA17 - Variabilité inter-technique des protéines du fibrotest/actitest chez les malades atteints d’hépatite chronique C (2005) (0)
- O.037 Prediction of HCV-related morbidity and mortality burden in France using the back-calculation method (2006) (0)
- P1067 : Associations between antidiabetic and statin therapy and liver histology in patients with type 2 diabetes and non-alcoholic fatty liver disease (2015) (0)
- CO 25-Une réduction précoce et profonde de la charge virale est associée à une efficacité virologique et clinique optimale à 1 an, chez les malades ayant une hépatite B chronique traités par analogues nucléosidiques (2006) (0)
- CA28 - TRAITEMENT DE L'HÉPATITE C CHEZ LES MALADES TOXICOMANES : EXPÉRIENCE AU SEIN D'UN CSST (2005) (0)
- 727 FIBROTEST AND LIVER STIFFNESS MEASUREMENT (LSM) BY FIBROSCAN FIBROSIS DIAGNOSIS IN HIV–HCV CO-INFECTED PATIENTS FROM THE FRENCH HepaVIH COHORT. HIV-TREATMENTS IMPACT ON NON-INVASIVE BIOMARKERS (2013) (0)
- P.389 Valeur pronostique d’une classification en trois classes par le FibroTest (FT) pour les complications et le décès lié à la maladie chez les patients atteints d’hépatite chronique C (VHC), B (VHB) et maladie alcoolique du foie (MAF) (2009) (0)
- Sarcoïdose et traitement par les interférons : Une possible relation de causalité. À propos de cinq observations issues de deux cohortes de 60 et 1 159 patients (2002) (0)
- Valeur diagnostique des marqueurs biochimiques de la fibrose (Fibrotest) pour l'évaluation de la fibrose hépatique dans la maladie alcoolique du foie (MAF) (2008) (0)
- P.365 Biochemical markers of liver fibrosis and activity in patients with chronic hepatitis C and mixed cryoglobulinemia systemic vasculitis (2006) (0)
- Effets du traitement antiviral sur l'histologie chez les patients contaminés par le virus de l'hépatite C (2002) (0)
- Fibroscopie d'urgence dans les hémorragies digestives des cirrhotiques. Réflexions critiques. (1980) (0)
- CA 22-Standardisation analytique, une nécessité internationale pour homogénéiser les résultats des marqueurs sanguins des lésions histologiques du foie : application aux composants du Nash-Fibrosure (2006) (0)
- [Results and indications of liver transplantation in alcoholic cirrhosis]. (1999) (0)
- Carcinome hépatocellulaire et mortalité hépatique dans la cirrhose associée au surpoids (2008) (0)
- Population clonale B dans le sang et le foie de patients chroniquement infectéspar le virus de l'hépatite C (2001) (0)
- Modélisation du ratio coût efficacité dans le dépistage du cancer colorectal chez les personnes asymptomatiques et à risque moyen par Hemoccult II* versus Coloscopie optique versus Coloscanner (2008) (0)
- Étude du protéome sérique dans les hépatopathies chroniques virales c (HCV) par la méthode du SELDI-TOF ProteinChip : identification de nouveaux marqueurs non invasifs de fibrose (2008) (0)
- Hypertension portale : prophylaxie primaire (1998) (0)
- La vie sans biopsie hépatique est possible chez les malades ayant une hépatite chronique C : validation des marqueurs biochimiques de la fibrose et de l'activité chez 1 570 malades et donneurs du sang (2008) (0)
- P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey (2015) (0)
- [Evaluation by a randomized trial of the usefulness of endoscopy after treatment of a flare-up of non-severe esophagitis]. (1997) (0)
- [Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori]. (1995) (0)
- Les interférons ont-ils une action antifibrosante ? (2002) (0)
- Effect of an on-demand-medication by effervescent cimetidine 200 mg in the course of symptomatic gastro-esophagal reflux: Results of a randomized trial in general practice (1995) (0)
- Ballonnements et douleurs abdominales : physiopathogie et stratégie thérapeutique (1992) (0)
- Response to hewitt et al: Retrieval of randomized clinical trials in liver disease (1988) (0)
- 1317 PERFORMANCE AND LIMITATIONS OF STEATOSIS MARKERS IN PATIENTS WITH NAFLD (2012) (0)
- Iconography : Mutants pré-C du VHB (2008) (0)
- Prévalence de la toxicité hépatique des médicaments : ALAT et seuil d’alerte (2011) (0)
- Intérêt d'un indice thérapeutique cumulé (ITC) pour les malades de réanimation: comparaison avec le système TISS et les points oméga (1987) (0)
- LA META-ANALYSE : UN OUTIL AU SERVICE DE L'HEPATO-GASTROENTEROLOGIE CLINIQUE (1991) (0)
- P.390 Valeur pronostique du FibroTest pour les complications à 10 ans chez les patients avec une hépatite chronique C (HCC) (2009) (0)
- Traitement et prévention de l'hépatite C (2000) (0)
- P076 - Identification des caractéristiques et du coût des soins de santé des patients à coût élevé atteints de NAFLD: étude observationnelle utilisant la cohorte CONSTANCES (2023) (0)
- Spectrum of NAFLD Severity in a Large Population using Software-Combined Tests of Steatosis, Necroinflammatory Activity, and Fibrosis (Fibromax) in Comparison with Patients with Chronic Hepatitis C (2016) (0)
- Effet de la gomme guar sur l'absorption de l'éthanol chez l'homme. (1983) (0)
- Recurrent bleeding and propranolol? (1983) (0)
- Pancréatites aiguës nécrosantes: la chirurgie de la nécrose aggrave le pronostic (1985) (0)
- Iconography : Statut cagA et virulence des souches de Helicobacter pylori (2008) (0)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression (2010) (0)
- Hépatite c: le traitement : Hépatites C et nouveaux virus (1999) (0)
- The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests". (2009) (0)
- O.125 Management of treatment non-responders in chronic hepatitis C (2006) (0)
- Four years outcomes of Baveno VI low risk cirrhotic patients (2018) (0)
- CA 52 - ÉUDE RANDOMISÉE COMPARANT L'EFFICACITÉ DE LA TELBIVUDINE (LDT) À L'ADÉFOVIR (ADV) DANS L'HÉPATITE CHRONIQUE B AGHBE POSITIF : RÉSULTATS 24 SEMAINES (2006) (0)
- Suivi prospectif des discordances entre les marqueurs biochimiques et la biopsie hépatique chez les malades ayant une hépatite chronique C (HCC) (2008) (0)
- Valeur diagnostique des marqueurs biochimiques (FIBROTEST-ACTITEST) dans les maladies chroniques du foie : une alternative non-invasive à la biopsie du foie (2008) (0)
- Emergence of hepatitis C virus resistance associated variants in patients failing direct acting antivirals by ultra-deep sequencing (2018) (0)
- Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest (FT)/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC 3 Program (2010) (0)
- Impact du statut vitaminique D sur la fibrose hépatique chez les patients co-infectés VIH-VHC (2011) (0)
- Evaluation prospective du traitement « a la carte » par PEG-interféron alpha 2B et ribavirine chez les malades atteints d'une hépatite chronique C (HCC) (2008) (0)
- Iconography : Influence des événements de la vie génitale sur les lésions hépatiques des femmes atteintes d'hépatite chronique C (2008) (0)
- C016 - Valeur diagnostique d’un nouveau marqueur biochimique (AshTest) pour la prédiction de l’hépatite alcoolique aiguë chez les buveurs excessifs (2005) (0)
- CA25 - Variabilité d’échantillonnage de la biopsie hépatique dans les stéatopathies métaboliques (2004) (0)
- Fatigue et fibromyalgie chez les patients chroniquement infectés par le virus de l'hépatite C (2000) (0)
- Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235] (2013) (0)
- Devenir des patients après guérison d’une œsophagite Etude prospective de 1 030 patients pendant 6 mois (1991) (0)
- Faut-il intuber les malades atteints de cirrhose ? (2008) (0)
- Qu'attendre des systèmes experts pour le diagnostic des troubles fonctionnels intestinaux (1990) (0)
- [Effect of guar gum on absorption of ethanol in man]. (1983) (0)
- Rôle des polymorphismes des gènes impliqués dans le métabolisme de la vitamine D dans la survenue des manifestations extrahépatiques au cours de l’infection par le virus de l’hépatite C (2011) (0)
- Nodular regenerative hyperplasia : The main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities q (2007) (0)
- Hépatite virale C chronique: contribution du médecin généraliste à l'éducation thérapeutique (2012) (0)
- Impact des traitements antiviraux sur les manifestations extrahépatiques des patients avec hépatite C chronique (2001) (0)
- Une hépatite à cytomégalovirus n’est jamais chronique, et peut en cacher une autre ! (2001) (0)
- ampling Variability of Liver Biopsy in Nonalcoholic Fatty iver Disease (0)
- The Cochrane Hepato-Biliary Group: Evidence medicine for all (1998) (0)
- Conséquences hépatiques des maladies sexuellement transmissibles (1983) (0)
- [Pre-C mutations of the HBV]. (2002) (0)
- Liver stiffness, platelets, and spleen size is reliable in nondecompensated cirrhotic patients. (2013) (0)
- [Is liver biopsy still useful?]. (2007) (0)
- Relationships between liver histologic lesions and portal hypertension in patients with alcoholic cirrhosis (1985) (0)
- 1022 OVERESTIMATION OF “PURE” NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AS A CAUSE OF LIVER FIBROSIS (AF) USING ALCOHOL CONSUMPTION ESTIMATED BY SELF DECLARATION (SD) (2009) (0)
- [Utilization of vegetable dietary fibers in therapeutic gastroenterology]. (1979) (0)
- P0043 : Rate of employment after liver transplantation in france: A single centre study (2015) (0)
- High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. (2023) (0)
- 855 DIAGNOSTIC VALUE OF BIOMARKERS (FIBROTEST, ACHTEST, STEATOTEST AND NASHTEST) FOR THE PREDICTION OF LIVER INJURY IN 494 PATIENTS WITH SEVERE OBESITY (2011) (0)
- DOES PNEUMOPERITONEUM IMPAIR DIAPHRAGMATIC FUNCTION (1984) (0)
- [Controlled study of pentaerythritol in the treatment of subjects with functional intestinal disorders of the constipation type]. (1983) (0)
- 1359 ASSOCIATION BETWEEN LIVER FIBROSIS AND DECREASED APOLIPOPROTEIN-A1 IN A 7-YEARS PROSPECTIVE STUDY. COULD IT EXPLAIN CARDIOVASCULAR-RELATED RISK WITH FIBROSIS PROGRESSION IN TYPE-2 DIABETIC PATIENTS? (2013) (0)
- 1156 IS TRUTH SURVIVAL IN HEPATOLOGY ASSOCIATED WITH HIRSCH INDEX (H) (2010) (0)
- FibroTest (FT) has similar accuracy for cirrhosis in ‘intention‐to‐diagnose’ which is superior to transient elastography (TE) in chronic hepatitis B. (2014) (0)
- Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects Early Stages of Steatosis and Fibrosis (2023) (0)
- A Biliary Milestone: Functional Expression of the Human Bile Salt Export Pump (2002) (0)
- [Comparative effects of lemon and apple pectins on oral glucose tolerance test in patients after gastric surgery]. (1980) (0)
- [Can metabolic steatohepatitis be treated?]. (2007) (0)
- GM-018 Improvement plan for daa prescription compliance in the pitiÉ-salpÊtriÈre hospital (2016) (0)
- Management of patients coinfected by HCV and HIV. (2005) (0)
- 413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3 (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thierry Poynard?
Thierry Poynard is affiliated with the following schools:
